Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions

Abstract

Compositions useful for treating membrane-associated diseases, conditions, and disorders, including inflammatory diseases, dry mouth, primary ciliary dyskinesia and platelet aggregating disorders, are disclosed which comprise at least one lantibiotic compound. Also disclosed are pharmaceutical compositions and methods of treatment for membrane-associated diseases such as inflammation and dermal irritation, as well as use of such compositions in the treatment of membrane-associated diseases, wherein the pharmaceutical compositions contain at least one lantibiotic.

1 . A method for treating a membrane-associated disease or disorder in a mammal comprising administering an effective amount of a lantibiotic to the mammal, wherein the membrane associated disease is xerostomia, ciliary dyskenesia or platelet aggregation disorder. 
     
     
         2 . A method for treating an inflammatory disease or disorder in a mammal comprising administering an effective amount of a lantibiotic to the mammal, wherein the inflammation occurs in a region of the body selected from the group consisting of: kidney, liver, stomach, bladder, bowels, pancreas, thyroid, heart, skin, central nervous system, immune system, joint, mouth, ears, nose, throat, pharynx, larynx, trachea, and sinuses. 
     
     
         3 . The method of  claim 1  or  2 , wherein the lantibiotic is the compound of Formula I: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein: 
       Xaa 1 , Xaa 2 , Xaa 3 , Xaa 4 , Xaa 5 , Xaa 6 , Xaa 7 , Xaa 8 , and Xaa 9  are independently selected from natural or synthetic amino acids, including but not limited to alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, lanthionine, and β-methyllanthionine. 
     
     
         4 . The method of  claim 1  or  2 , wherein the lantibiotic is a Type A or Type B lantibiotic. 
     
     
         5 . The method of  claim 4 , wherein the lantibiotic is a Type B lantibiotic. 
     
     
         6 . The method of  claim 5 , wherein the Type B lantibiotic is duramycin. 
     
     
         7 . The method of  claim 1  or  2 , wherein the lantibiotic is administered in combination or alternation with an aminoglycoside. 
     
     
         8 . The method of  claim 7 , wherein the aminoglycoside is tobramycin. 
     
     
         9 . The method of  claim 1 , wherein the membrane-associated disease is xerostomia. 
     
     
         10 . The method of  claim 9 , wherein the xerostomia is caused by another drug or pharmaceutical agent. 
     
     
         11 . The method of  claim 10 , wherein the drug or pharmaceutical agent is selected from the group consisting of anticholinergics, antispasmodics, antihypertensives, antidepressants, anticonvulsants, pain killers, anti-rejection drugs, anti-pyschotics, decongestants, and antihistamines. 
     
     
         12 . The method of  claim 9 , wherein the lantibiotic is administered orally. 
     
     
         13 . The method of  claim 12 , wherein the lantibiotic is administered as a lozenge. 
     
     
         14 . The method of  claim 9 , wherein the xerostomia is caused by an abnormal physiological state. 
     
     
         15 . The method of  claim 14 , wherein the physiological state is selected from the group consisting of an infection, elevated stress, anxiety, depression, endocrine disease and autoimmune disorder. 
     
     
         16 . The method of  claim 1 , wherein the membrane-associated disease is ciliary dyskenesia. 
     
     
         17 . The method of  claim 16 , wherein the ciliary dyskenesia is a primary ciliary dyskenesia. 
     
     
         18 . The method of  claim 16 , wherein the ciliary dyskenesia is a secondary ciliary dyskenesia. 
     
     
         19 . The method of  claim 16 , wherein the ciliary dyskenesia affects the mouth, ears, nose, throat, sinuses, upper airways, genito-urinary tract, spermatozoa, ovaries, or fallopian tubes. 
     
     
         20 . The method of  claim 1 , wherein the membrane-associated disease is a platelet aggregating disease. 
     
     
         21 . The method of  claim 20 , wherein the platelet aggregating disease is selected from the group consisting of atherosclerotic cardiovascular disease, coronary artery disease, cerebral vascular disease, kidney disease, abdominal vascular insufficiency, and peripheral vascular disease. 
     
     
         22 . The method of  claim 2 , wherein the inflammatory disease is an autoimmune disease. 
     
     
         23 . The method of  claim 2 , wherein the inflammatory disease is arthritis.